AKT1 and renal fibrosis: Combined with the results of our network pharmacology, that is, both AKT1 and IL‐6 have a good binding ability with various active ingredients of GBXZF, we speculated that GBXZF could reduce the inflammatory response and improve renal fibrosis by upregulating the PI3K/AKT signaling pathway.